OECD Home › Directorate for Science, Technology and Industry › Science and technology policy › Latest Documents
An ageing population brings new challenges both to healthcare systems and to medicine in terms of the increased manifestation of specific diseases primarily seen in the elderly. Biomedical innovation, and in particular research into "omics technologies", offers the promise of new means of detection, prevention and treatment of age-related disabilities and diseases.
This report describes recent trends in government and institutional level policies to enhance the transfer and exploitation of public research. It also benchmarks a set of countries, universities and public research institutions based on both traditional and new indicators.
English, PDF, 913kb
As the number of people affected from dementia continues to climb across the world as populations age, the cost for health systems rises too. OECD countries account for nearly half the global cases of dementia today and have a particular responsibility in addressing this challenge.
This paper presents the findings of a survey of 25 countries. It provides a snapshot of current national or regional policy and research programmes designed to stimulate the growth of nanotechnology applications in diverse sectors of the economy while addressing the potential risks and the ethical and social challenges the technology might raise.
This page presents the OECD statistical work on human resources in science and technology, more specifically the OECD/UNESCO Institute for Statistics/Eurostat project on careers of doctorate holders.
Statistics on biotechnology firms, biotechnology R&D (including public sector expenditures), biotech applications and patents.
Patent indicators are used to map aspects of the innovative performance and technological progress of countries, regions or certain specific domains and technology fields.
The aim of this consultation, held on 20-21 June 2013 in Oxford (UK), was to stimulate discussion at the highest possible level of expert engagement in setting out an agenda for OECD action to accelerate innovation for Alzheimer’s disease and dementia.
The economic and social impact of chronic brain disorders such as Alzheimer’s and other neurodegenerative diseases will become the #1 public health problem worldwide by 2050, directly affecting 100 million people. Ongoing demographic trends, namely ageing populations, are leading to the unprecedented expansion of consumer demand for healthcare services, which will confront a serious crisis in a climate of shrinking resources.
Countries/regions have begun to develop and refine regulatory approaches for foods and medical products and invest in regulatory science and other research efforts to support the responsible development of nanotechnology in these areas. This paper inventories and analyses regulatory approaches, legislative regimes and government-sponsored research programmes and infrastructure in foods and medical products that involve nanotechnology.